<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962893</url>
  </required_header>
  <id_info>
    <org_study_id>VLP-58-1023-Al-K3-PII</org_study_id>
    <nct_id>NCT04962893</nct_id>
  </id_info>
  <brief_title>Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ihsan GURSEL, PhD, Prof.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Scientific and Technological Research Council of Turkey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nobel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MonitorCRO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scientific and Technological Research Council of Turkey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, parallel dose assigned, double blind, multi center, Phase II study&#xD;
      assessing the efficacy, safety, and immunogenicity of VLP vaccine (Authentic and Alpha&#xD;
      variants) in adults between 18 and 59 years who are healthy or have medically stable chronic&#xD;
      diseases and who have no known history of SARS-CoV-2 infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the humoral and cellular immune response of&#xD;
      VLP vaccine candidates (harboring M, N, E, and HexaPro S antigens of the virus), as an&#xD;
      efficacy criteria.&#xD;
&#xD;
      Approximately 330 subjects will be randomized in a 1:1:1 ratio to receive two doses of 40 mcg&#xD;
      VLP vaccine for Wuhan (n=110) or 40 mcg VLP vaccine for Alpha (British) variant (n=110) or 40&#xD;
      mcg VLP vaccine for Wuhan+Alpha variant (n=110) 21 days apart.&#xD;
&#xD;
      The study will be completed in 14 months.&#xD;
&#xD;
      All injections will be done subcutaneously.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of efficacy</measure>
    <time_frame>On Day 14 after booster dose administration</time_frame>
    <description>Comparison of antibody responses of participants to a cohort of standard convalescent serum samples obtained from World Health Organization (WHO).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of efficacy</measure>
    <time_frame>On Day 28 after booster dose administration</time_frame>
    <description>Comparison of antibody responses of participants to a cohort of standard convalescent serum samples obtained from World Health Organization (WHO).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific antibody (IgG) response</measure>
    <time_frame>On Day 14 after booster dose administration</time_frame>
    <description>SARS-CoV-2 Spike/S1 or RBD antibody titers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific antibody (IgG) response</measure>
    <time_frame>On Day 28 after booster dose administration</time_frame>
    <description>SARS-CoV-2 Spike/S1 or RBD antibody titers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody response</measure>
    <time_frame>On Day 14 after booster dose administration</time_frame>
    <description>Neutralizing antibody titer against anti-Spike protein by virus neutralization method developed against SARS-CoV-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody response</measure>
    <time_frame>On Day 28 after booster dose administration</time_frame>
    <description>Neutralizing antibody titer against anti-Spike protein by virus neutralization method developed against SARS-CoV-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular immune response</measure>
    <time_frame>Before first dose administration, on Day 14 after booster dose administration</time_frame>
    <description>ELISPOT: Interferon-γ (IFN-γ) positive level of T-cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Until Month 12 after booster dose administration</time_frame>
    <description>Local and systemic AEs in all vaccine groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>Until Month 12 after booster dose administration</time_frame>
    <description>SAEs in all vaccine groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific antibody (IgG) response</measure>
    <time_frame>Before first and booster dose administration, at Month 3, Month 6, Month 9 and Month 12 after booster dose</time_frame>
    <description>SARS-CoV-2 Spike/S1 or RBD antibody titers</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>VLP-Wuhan group (Group V1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLP-Alpha (British) variant group (Group V2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLP-Wuhan+Alpha group (Group V3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan and Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.&#xD;
Initial vaccination with Wuhan followed by a booster of Alpha variant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 VLP Vaccine-Wuhan</intervention_name>
    <description>Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus</description>
    <arm_group_label>VLP-Wuhan group (Group V1)</arm_group_label>
    <other_name>Authentic VLP Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 VLP Vaccine-Alpha (British) variant</intervention_name>
    <description>Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus</description>
    <arm_group_label>VLP-Alpha (British) variant group (Group V2)</arm_group_label>
    <other_name>Alpha Variant VLP Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant</intervention_name>
    <description>Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants</description>
    <arm_group_label>VLP-Wuhan+Alpha group (Group V3)</arm_group_label>
    <other_name>Combination of Authentic and Alpha VLP Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for the study, each participant must satisfy all the following criteria:&#xD;
&#xD;
          1. Female and/or male participant who is informed and about his/her participation and who&#xD;
             agrees to give his/her written informed consent.&#xD;
&#xD;
          2. Aged between 18 and 59 years.&#xD;
&#xD;
          3. Negative Immunoglobulin G (IgG)/Immunoglobulin M (IgM) antibody for COVID-19.&#xD;
&#xD;
          4. Negative COVID-19 quantitative polymerase chain reaction (qPCR) test result.&#xD;
&#xD;
          5. Able to comply with all scheduled visits, vaccination plan, laboratory tests,&#xD;
             lifestyle considerations, and other study procedures.&#xD;
&#xD;
          6. Negative blood test for hepatitis B (HBV), hepatitis C (HCV) and human&#xD;
             immunodeficiency virus (HIV) at screening period.&#xD;
&#xD;
          7. Body temperature &lt; 37.2°C.&#xD;
&#xD;
          8. Body Mass Index (BMI) ranged between 18-35 kg/m2.&#xD;
&#xD;
          9. Clinical laboratory test results within the reference range of the laboratory or&#xD;
             clinically non-significant (complete blood count (CBC), alanine aminotransferase&#xD;
             (ALT), aspartate aminotransferase (AST), total bilirubin, urea, creatinine, and&#xD;
             fasting glucose) or any laboratory parameters defined in the study protocol.&#xD;
&#xD;
         10. Good general health as determined by physical examination, laboratory screening, and&#xD;
             review of medical history within 14 days prior to participation.&#xD;
&#xD;
         11. Female participants of childbearing potential may be enrolled in the study if the&#xD;
             subject fulfils all the following criteria:&#xD;
&#xD;
               -  Have a negative pregnancy test on the day of screening and prior to each study&#xD;
                  vaccine administration.&#xD;
&#xD;
               -  Use an effective contraceptive method for at least 30 days prior to first dose of&#xD;
                  study vaccine and agree to continue using one highly effective form of birth&#xD;
                  control through 6 months after the administration of the last dose of study&#xD;
                  vaccine.&#xD;
&#xD;
         12. Female participants of non-childbearing potential may be enrolled in the study.&#xD;
             Non-childbearing potential is defined as postmenopausal (defined as amenorrhea for ≥12&#xD;
             consecutive months prior to Screening without an alternative medical cause) or&#xD;
             surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy).&#xD;
&#xD;
         13. Male participants who agree to use an effective contraceptive method during the study&#xD;
             period and until 6 months after the last dose of study vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants with any of the following criteria will be excluded:&#xD;
&#xD;
          1. History of laboratory-confirmed SARS-COV-2 infection.&#xD;
&#xD;
          2. History of seizures, encephalopathy, or psychosis.&#xD;
&#xD;
          3. Known or suspected allergy or history of anaphylaxis or other serious adverse&#xD;
             reactions to any vaccine or study vaccine and/or any other excipients of the vaccine.&#xD;
&#xD;
          4. Pregnant, breastfeeding or planning to become pregnant within 6 months after the study&#xD;
             vaccine administration.&#xD;
&#xD;
          5. Suspected active infection or other acute illness, including fever &gt; 37.2°C.&#xD;
&#xD;
          6. Any presence of clinical relevance of cardiovascular disease (including but not&#xD;
             limited to arrythmia, myocardial infarction, uncontrolled hypertension, coronary&#xD;
             artery disease, or congestive heart failure).&#xD;
&#xD;
          7. Any presence of clinical relevance of serious chronic disease [asthma, diabetes,&#xD;
             thyroid diseases etc.).&#xD;
&#xD;
          8. Any presence of clinical relevance of congenital or acquired angioedema.&#xD;
&#xD;
          9. Diagnosis of immunodeficiency.&#xD;
&#xD;
         10. Diagnosis of bleeding diathesis.&#xD;
&#xD;
         11. Use of immunosuppressive medications, anti-allergic therapy, cytotoxic therapy,&#xD;
             inhaler corticosteroids (excluding allergic rhinitis or topical steroid ointments).&#xD;
&#xD;
         12. Those who received blood/plasma products or immunoglobulins and/or blood transfusion&#xD;
             within the last 6 months.&#xD;
&#xD;
         13. Those who participated in another vaccine study or received an&#xD;
             investigational/experimental drug within 1 month prior to study entry.&#xD;
&#xD;
         14. History of any live vaccine within 1 month prior to study participation.&#xD;
&#xD;
         15. History of any inactivated vaccine within 1 month prior to study participation.&#xD;
&#xD;
         16. Use of active tuberculosis treatment.&#xD;
&#xD;
         17. According to the investigator's judgement, those who have any condition (medical,&#xD;
             psychological, social, etc.) that may impair the subject's compliance with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fevzi ALTUNTAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HEAD OF ONCOLOGY HOSPITAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fevzi ALTUNTAS, MD, Prof</last_name>
    <phone>+(90) 532 658 80 50</phone>
    <email>faltuntas@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Abdurahman Yurtaslan Ankara Oncology Training and Research Hospital Phase I Clinical Study Center</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fevzi ALTUNTAS, MD, Prof</last_name>
      <phone>+905326588050</phone>
      <email>faltuntas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Sciences University İstanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital</name>
      <address>
        <city>İstanbul</city>
        <zip>34020</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa ÇÖRTÜK, MD,Assc.Prof</last_name>
      <phone>+90 533 572 2023</phone>
      <email>mcortuk@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Research and Application Hospital Infectious Disease and Clinical Microbiology Department</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sıla AKHAN, MD, Prof</last_name>
      <phone>+90 532 266 6535</phone>
      <email>cetinakhan@yahoo.com.tr</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Scientific and Technological Research Council of Turkey</investigator_affiliation>
    <investigator_full_name>Ihsan GURSEL, PhD, Prof.</investigator_full_name>
    <investigator_title>Co- Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Virus-like Particles harboring S, M, N, E antigens</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>K3-CpG ODN</keyword>
  <keyword>Alum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

